Gruia Stoica's Grampet gains control of 74 pct of Polisano Pharmaceuticals, plans to invest EUR 25 mln in new oncology division

The Grampet group, the largest railway group and private logistic operator in Romania and Southeastern Europe, controlled by businessman Griuia Stoica, has increased its stake in Polisano Pharmaceuticals in Sibiu from 20 to 74 percent.

“The investment comes after two consecutive acquisitions of minority holdings over the past year, when we better understood the needs and development potential of this plant. So I got the confirmation that the initial decision to take over one of the best known brands in the Romanian pharmacy industry and to lead it to the next level of development was right,” says Gruia Stoica, president of Grampet Group.

According to Stoica, there are significant resources available to expand the business, aimed to bring Polisano Pharmaceuticals first to Central and South Eastern Europe to produce the drugs needed to treat cancer.

The structure of the new shareholders is 74 percent Grampet Group, the remaining 26 percent being held by the Muntean family and the lawyer Remus Borza. The management team remains unchanged, benefiting from the confidence of the shareholders that they have the ability and know-how to meet their established business goals.

”We are preparing the launch of the first line of solid oncology drug production in the first half of next year, following an investment of EUR 25 million for a capacity of approximately 10 million therapeutic units per year. At the same time, by the end of 2019, preparations will be completed for production on injectable liquid oncology lines existing in the factory in Sibiu, ”added Gruia Stoica.

About 30 percent of Polisano Pharmaceuticals’ production will go to the domestic market, with the remainder being dedicated to export to the 35 markets Polisano is already working on, but also to other countries as the company expands its partnerships.

”We are currently working with over 100 physicians and pharmacies and constantly investing in innovation, looking for the most modern, diverse and affordable pharmaceutical formulas. We trust that the new shareholders’ structure supports Polisano’s mission to improve the lives of as many people as possible. At the same time, we hope to make a significant contribution to mitigating the oncology crisis on the Romanian market, which patients feel increasingly acute in recent years, ”says Roxana Manole, CEO of Polisano Pharmaceuticals.

The factory in Sibiu has 160 employees and an area of 33,000 square meters, being equipped with state-of-the-art manufacturing lines. Currently it has a production capacity equivalent to over 500 million therapeutic units and produces over 50 own brands of food supplements and OTCs distributed in 35 countries.